We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effects of Doxofylline on Pulmonary Function and Serum Levels of TGF-beta, MMP-9 and TIMP-1 in Patients with Chronic Obstructive Pulmonary Disease.
- Authors
Juwei Zhang; Pingping Yang; Yanfei Jiang
- Abstract
To investigate the effects of doxofylline on pulmonary function, Hemorheology and transform growth factor-β (TGF-β), matrix metalloproteinase-9 (MMP-9) and tissue suppressor Metalloproteinase-1 (TIMP-1) levels in patients with chronic obstructive pulmonary disease (COPD). Totally, 102 patients with COPD, treated in our hospital from February 2015 to January 2018, were randomly divided into an observation group and a control group according to the method of random number table, with 51 patients in either group. Patients in the control group were given conventional treatments such as oxygen inhalation, Qiangli Pipa Syrupe, bronchodilator (aminophylline) and antibiotics to prevent infection. The patients in the observation group were treated with doxofylline additionally. The patients in both groups were treated continuously for 4 weeks. For the patients in both groups, the clinical efficacies after treatment, change on pulmonary function [forced vital capacity (FVC), maximal mid-expiratory flow curve (MMEF), peak exhalation flow (PEF) and mean pulmonary arterial pressure (MPAP)], changes of TGF-β, MMP-9 and TIMP-1TGF-β, arterial blood gas indicator [arterial oxygen partial pressure (PaO2) and carbon dioxide partial pressure (PaCO2)] were compared, and the occurrence of adverse reactions during the treatment were observed. After the treatment, the total effective rate was 96.08% in the observation group, which was significantly higher than 80.39% in the control group (P <0.05). Compared with those before the treatment, the levels of FVC, FEV1, MMEF and PEF in both groups increased significantly, and the levels of MPAP decreased significantly after the treatment. The changes of the above indicators were significantly greater in the observation group than in the control group, and the differences were statistically significant (P < 0.05). Compared with those before treatment, the serum levels of TGF-β, MMP-9 and TIMP-1 in both groups significantly decreased after the treatment, and the observation group was significantly better than the control group (P <0.05). Compared with those before treatment, PaO2 level significantly increased, while PaCO2 level significantly decreased in both groups after the treatment. The above indicators were better in the observation group than in the control group, of which the differences were statistically significant (P <0.01). The incidence of adverse reactions in the observation group was 3.92% (two cases), which was much lower than 17.65% (nine cases) in the control group (P <0.05). The clinical effect of doxofylline in the treatment of COPD is obvious, which can significantly reduce the hemorheology indicators and serum levels of TGF-β, MMP-9 and TIMP-1 in the patients and significantly improve the pulmonary function of the patients with high safety and wide clinical application value.
- Subjects
PULMONARY function tests; HEMORHEOLOGY; TRANSFORMING growth factors-beta; OBSTRUCTIVE lung diseases; METALLOPROTEINASES
- Publication
Acta Microscopica, 2020, Vol 29, Issue 2, p626
- ISSN
0798-4545
- Publication type
Article